Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL

Diffuse Large B Cell Lymphoma Clinical Trial

— MT-3724NHL001  

Official title:

Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02361346
• Other study ID #: MT-3724_NHL_001
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: February 2015
• Est. completion date: March 22, 2021

Study information

• Verified date: July 2022
• Source: Molecular Templates, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of MT-3724 in subjects with relapsed or refractory B-Cell NHL or relapsed and refractory CLL (Part 1 only) and relapsed and refractory DLBCL (Part 2 and Part 3). Part 3 evaluates the efficacy of MT-3724.

Description:

This is a three-part Phase 2 study Part 1: (MT-3724 Dose Escalation) Define the maximum tolerated dose (MTD) of MT-3724 [Completed] Part 2: (MTD Expansion Cohort) Confirm the safety and tolerability of the MTD of MT-3724 in the MTD Expansion Cohort. Part 3: (Phase 2 MTD Expansion Cohort) Determine the efficacy of MT-3724 as monotherapy in subjects with relapsed or refractory DLBCL based on the overall response rate (ORR) by the revised Lugano Classification for Lymphoma adjusted according to LYRIC. It is anticipated that up to 100 patients will be enrolled in Part 3. Treatment will continue for up to six 21 days cycles. If the subject exhibits SD, CR or PR after the end of Cycle 6 and the investigator determines that the benefit-risk ratio is favorable, then the treatment with MT-3724 may be continued after discussion with the sponsor.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 38
• Est. completion date: March 22, 2021
• Est. primary completion date: March 22, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants must be informed about the study and fully consent to participation as demonstrated by signing the written ICF before any screening procedure.
• Male and female participants >= 18 years of age at the time of informed consent.
• Participants must have relapsed or refractory Diffuse large B cell lymphoma (DLBCL) according to the Revised European American Lymphoma/World Health Organization classification. Participants must have proof of cluster of differentiation 20 plus

(CD20+) DLBCL, based on either:

• a. historical biopsies (obtained with diagnosis of relapsed or refractory disease), or
• b. fresh biopsies
• c. bone marrow biopsy, excisional lymph node biopsy, and core biopsy of any involved organ are all acceptable methods; Fine Needle Aspirate is not acceptable.
• Participants must have received at least 2 standard of care (SoC) regimens (including anti-CD20 antibody therapy) appropriate for DLBCL treatment.
• a. Participants whose prior therapy includes chimeric antigen receptor T-cell (CAR-T-cell) therapy are eligible.
• b. Participants who underwent stem cell transplant (SCT) > 100 days for autologous SCT or > 180 days for allogeneic SCT before study drug administration.
• c. Participants who have been ineligible for SoC DLBCL treatments may be eligible at the investigator's discretion, upon sponsor approval.
• Participants must have at least 1 bi-dimensional tumor lesion at screening that is measurable by computerized tomography (CT) and/or magnetic resonance imaging (MRI) according to the Lugano criteria. Bi-dimensionally measurable tumor lesion by CT and/or MRI is defined as longest diameter of > 1.5 centimeters (cm) for lymph nodes and > 1.0 cm for extranodal disease.
• Participants must have life expectancy of > 3 months from the start of treatment.
• Participants must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
• Participants must have met ALL the following laboratory criteria:
• a. absolute neutrophil count (ANC) >= 1.0 × 10^9 cells per liter with no myeloid growth factors (granulocyte colony-stimulating factor [G-CSF] or granulocyte-macrophage colony-stimulating factor preparations) administered within 2 weeks of Cycle 1 Day 1.
• b. platelet count >= 50 × 10^9 cells per liter with no Thrombopoietin-receptor agonists agents or platelet transfusions given within 2 weeks of Cycle 1 Day 1.
• c. hemoglobin >= 8.0 grams per deciliter (g/dL) with no erythropoietin stimulating agents or peripheral red blood cell (PRBC) transfusions within 2 weeks of Cycle 1 Day 1
• d. creatinine clearance (CLcr) to be >= 50 milliliter per minute (ml/min) either measured or estimated using the Cockcroft-Gault formula.
• e. total bilirubin (or direct bilirubin for patients with Gilbert's disease < 1.5 × upper limit of normal (ULN)
• f. alanine transaminase (ALT) = 3.0 × ULN (or <= 5.0 x ULN if liver involvement).
• g. aspartate aminotransferase (AST) <= 3.0 × ULN (or <= 5.0 x ULN if liver involvement).
• h. international normalized ratio (INR) or prothrombin time (PT) <= 1.5 x ULN (unless on therapeutic anticoagulants).
• i. Activated partial thromboplastin time <= 1.5 x ULN (unless on therapeutic anticoagulants).
• Have adequate serum albumin, as determined by: a. albumin >= 3.0 g/dL.
• QT interval correction for heart rate using Fridericia's formula (QTcF) <= 480 milliseconds determined as the average of 3 QTcF values from the triplicate electrocardiogram (ECG) obtained at screening.
• Women of reproductive potential must have a negative highly sensitive pregnancy test within 72 hours before the start of treatment. Women who are postmenopausal or permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy) may be considered as not of reproductive potential.
• Participants of reproductive potential must agree either to abstain continuously from heterosexual intercourse or to use a highly effective birth control method from signing the informed consent until the short term follow-up (STFU) visit for females and until 90 days after the last dose of MT-3724 for males.
• Participants must be able to comply with all study-related procedures and medication use. Exclusion Criteria Prior or Current Therapies
• Received any amount of anti-CD20 monoclonal antibodies (mAbs) within the following

periods before the start of treatment:

• a. Rituximab (Rituxan®/MabThera® or rituximab biosimilar): within 84 days (12 weeks); if a participant has received rituximab within 37 weeks before the start of treatment, then serum rituximab level must be negative (< 500 nanograms per milliliter [ng/mL]) at screening.
• b. Obinutuzumab (Gazyva®/Gazyvaro®): 184 days c. Ofatumumab (Arzerra®): 88 days d. Any other anti-CD20 agents (eg, investigational agents), the washout period is 5 half-lives. The investigator must contact the medical monitor to discuss the most Compound: MT-3724 appropriate washout for non-approved CD20-targeting agents, where the half-life (t1/2) is not known.
• Received approved or investigational treatment for DLBCL within 4 weeks before the start of treatment. For small molecules (MW < 0.9 kilodaltons [kDa]), the washout is 5 half-lives or at least 2 weeks. Radioimmunoconjugates are excluded within 12 weeks before the start of treatment.
• Received radiation therapy to tumor lesions that would serve as target lesions (measurable disease) within 4 weeks before the start of treatment, unless the lesion exhibited objective progression between radiation therapy and screening according to the Lugano Classification o a. Palliative radiation therapy to non-target lesions may be permitted at the investigator's discretion after consultation with the medical monitor and sponsor.
• Require the use of systemic immune modulators during study treatment:
• a. Systemic immune modulators include, but are not limited to, systemic corticosteroids at doses > 20 milligrams per day (mg/day) of prednisone equivalent, cyclosporine and tacrolimus.
• b. The use of non-steroidal anti-inflammatory drugs (NSAIDS) is permitted.
• Received any live vaccines within 4 weeks before the start of treatment.
• Prior treatment with MT-3724. Medical History
• Current evidence of Common Terminology Criteria for Adverse Events (CTCAE) Grade > 1 toxicity (due to prior anticancer therapy) before the start of treatment, except for hair loss and those Grade 2 toxicities listed as permitted in other eligibility criteria.
• Current evidence of significant (CTCAE Grade = 2) infection or wound within 4 weeks before the start of treatment. a. Participants with Grade 2 infection that has stabilized or improved with oral anti-infectives before the start of treatment may be eligible at the sponsor's discretion.
• Known or suspected hypersensitivity to the study drug or excipients contained in the study drug formulation.
• Current evidence of hypersensitivity or other underlying illness requiring systemic corticosteroids at doses > 20 mg/day prednisone equivalent.
• Current evidence of uncontrolled human immunodeficiency syndrome (HIV), hepatitis B virus (HBV) or /hepatitis C virus (HCV) at screening. Serology testing is not required if seronegativity is documented in the medical history, and if there are no clinical signs suggestive of HIV or hepatitis infections, or suspected exposure. The following

exceptions apply for participants with positive viral serology:

• a. Participants with HIV and an undetectable viral load and CD4+ T-cell (CD4+) counts >= 350 cells per milliliter may be enrolled, but must be taking appropriate opportunistic infection prophylaxis, if clinically relevant.
• b. Participants with positive HBV serology are eligible if they have an undetectable viral load and the participant will receive antiviral prophylaxis for potential HBV reactivation per institutional guidelines.
• c. Participants with positive HCV serology are eligible if quantitative polymerase chain reaction (PCR) for plasma HCV ribonucleic acid (RNA) is below the lower limit of detection. Concurrent antiviral HCV treatment per institutional guidelines is allowed.
• Current evidence of incomplete recovery from surgery or radiotherapy before start of treatment, or planned surgery or radiotherapy from the start of treatment until the end of treatment (EoT) visit, except minor elective surgery deemed acceptable by the investigator or palliative radiation therapy to non-target lesions.
• History of cardiovascular, renal, hepatic or any other disease within 3 months before the start of treatment that in the investigator's opinion, may increase the risks associated with study participation or require treatments that may interfere with the conduct of the study or the interpretation of study results.
• History or current evidence of neoplastic disease that is histologically distinct from NHL, except cervical carcinoma in situ, superficial noninvasive bladder tumors, curatively treated Stage I-II non-melanoma skin cancer. Participants with prior, curatively treated cancer > 2 years ago before the start of treatment can be enrolled.
• Current evidence of new or growing brain or spinal metastases during screening.

Participants with known brain or spinal metastases may be eligible if they:

• a. Had radiotherapy or another appropriate therapy for the brain or spinal metastases; concurrent prophylactic treatment is allowed
• b. Neurologic symptoms must be stable and no worse than Grade 2
• c. Have evidence of stable brain or spinal disease on CT or MRI scan obtained within 4 weeks before signing the informed consent and compared with prior imaging results
• d. Do not require steroid therapy (or, if applicable, have been stable on dose of no more than prednisone 20 mg/day or equivalent by C1D1)
• Women who are pregnant or breastfeeding.
• History of non-adherence to the schedule of procedures or medication use. 18. Current evidence of Graft vs Host Disease
• History or current evidence of significant cardiovascular disease including, but not

limited to, the following conditions:

• a. Unstable angina (symptoms of angina at rest) or new-onset angina within 3 months before the start of treatment.
• b. Arterial thrombosis or pulmonary embolism within 3 months before the start of treatment.
• c. Myocardial infarction or stroke within 3 months before the start of treatment.
• d. Pericarditis (any CTCAE grade), pericardial effusion (CTCAE Grade >= 2), non-malignant pleural effusion (CTCAE Grade = 2) or malignant pleural effusion (CTCAE Grade >= 3) within 3 months before the start of treatment with MT-3724.
• e. Congestive heart failure (New York Heart Association [NYHA] Class III or IV) at screening or left ventricular ejection fraction (LVEF) <= 45 percent (%), assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 1 month before starting study treatment (inclusion of participants with LVEF between 40% to 45% should be discussed with the medical monitor and approved by the sponsor). (ECHO or MUGA performed within 6 months before screening and at least 28 days after the last cancer therapy is acceptable provided the participant has not received any potentially cardiotoxic agents since then).
• f. Cardiac arrhythmia requiring anti-arrhythmic therapy at screening. Participants receiving digoxin, calcium channel blockers, or beta-adrenergic blockers are eligible at the investigator's discretion after consultation with medical monitor and sponsor if the dose has been stable for >= 2 weeks before the start of treatment with MT-3724. Participants with sinus arrhythmia and infrequent premature ventricular contractions are eligible at the investigator's discretion.

Related Conditions & MeSH terms

• Blood Cancer
• Diffuse Large B Cell Lymphoma
• Hematologic Neoplasms
• Hematological Malignancy
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse
• Non-Hodgkin's B-cell Lymphoma
• Small Lymphocytic Leukemia

Intervention

Drug:
• MT-3724 Phase 1
Intravenous dosing Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.
• MT-3724 Phase 2
Intravenous dosing on Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 1 hour on each dosing day over 21 day cycle up to 6 cycles and then can be continued for 6 additional cycles.

Locations

Country	Name	City	State
Belarus	Grodno University Hospital	Grodno
Belarus	Minsk City Clinical Oncology Center	Minsk
Canada	Cross Cancer Institute	Edmonton	Alberta
Canada	Cancer Centre of Southeastern Ontario at Kingston General Hospital	Kingston	Ontario
Canada	Montreal Oncology Research	Quebec
Canada	Princess Margaret Cancer Centre	Toronto	Ontario
Georgia	LLC ARENSIA Exploratory Medicine	Tbilisi
Israel	Rabin Medical Center, Davidoff Cancer Center, Hemato-Oncology Institute	Petah-Tikva
Israel	Chaim Sheba Medical Center, Department of Hematology	Ramat Gan
Israel	The Tel Aviv Sourasky Medical Center, Department of Hematology and Bone Marrow Transplantation	Tel-Aviv
Moldova, Republic of	ARENSIA Exploratory Medicine,	Chisinau
Poland	Maria Sklodowska-Curie National Institute of Oncology - National Research Institute	Gliwice
Poland	University Hospital in Krakow, Teaching Unit of the Hematology Department	Kraków
Poland	Frederic Chopin Provincial Teaching Hospital, Teaching Department of Hematology	Rzeszów
Poland	Our Doctor Clinical Trials Center	Torun
Poland	Institute of Hematology and Transfusion Medicine, Department of Hematology	Warsaw
Poland	Jan Mikulicz Radecki University Hospital in Wroclaw, Department and Clinic of Hematology, Blood Neoplasms and Bone Marrow Transplantation	Wroclaw
Serbia	Clinical Center Kragujevac, Clinic of Hematology	Kragujevac
Serbia	Clinical Center of Vojvodina, Clinic of Hematology	Novi Sad
Spain	Catalan Institute of Oncology (ICO) - Hospital Duran i Reynals, Department of Clinical Hematology	Barcelona
Spain	University Hospital Vall d'Hebron (HUVH), Department of Hematology	Barcelona
Spain	Hospital Universitario QuironSalud Madrid	Madrid
Spain	University Hospital Virgen del Rocio (HUVR), Department of Hematology	Seville
Ukraine	Medical Center of Limited Liability Company "Medical Centre Named by Academician Yurii Spizhenko	Kyiv
United States	University of North Carolina	Chapel Hill	North Carolina
United States	University of Illinois, Cancer Center	Chicago	Illinois
United States	Columbus Regional Research Institute	Columbus	Georgia
United States	MD Anderson Cancer Center	Houston	Texas
United States	21st Century Oncology - Jacksonville	Jacksonville	Florida
United States	Norton Healthcare, Inc	Louisville	Kentucky
United States	Memorial Sloan-Kettering Cancer Center	New York	New York
United States	New York University Langone Medical Center	New York	New York
United States	Orlando Health, Inc.	Orlando	Florida
United States	Orlando Health, Inc.	Orlando	Florida
United States	BRCR Medical Center	Plantation	Florida
United States	UT Health San Antonio Cancer	San Antonio	Texas
United States	Healthcare Research Network III, LLC	Tinley Park	Illinois
United States	University of Arizona	Tucson	Arizona
United States	Carle Foundation Hospital	Urbana	Illinois
United States	ASCLEPES Research Centers	Weeki Wachee	Florida
United States	Innovative Clinical Research Institute, LLC	Whittier	California

Sponsors (1)

Lead Sponsor	Collaborator
Molecular Templates, Inc.

Countries where clinical trial is conducted

United States,  Belarus,  Canada,  Georgia,  Israel,  Moldova, Republic of,  Poland,  Serbia,  Spain,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1: Number of Participants With Dose Limiting Toxicities of a Single Cycle of MT-3724	The MTD is defined to be the dose cohort below which participants experience dose-limiting toxicities during cycle 1. Dose-limiting toxicities were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0	Days 1, 3, 5, 8, 10 and 12
Primary	Part 1 and 2: Maximum Observed Concentrations (Cmax) of MT-3274	Blood samples were collected at indicated timepoints for the determination of Cmax of MT-3274.	Part 1 and 2 : Days 1, 3 and 12
Primary	Part 1 and 2: Time to Achieve Cmax (Tmax) of MT-3724	Blood samples were collected at indicated timepoints for the determination of tmax.	Part 1 and 2: Days 1, 3 and 12
Primary	Part 1 and 2: Area Under the Plasma Concentration Time Curve From 0 to 4 Hours (AUC [0-4]), AUC (0-infinity) and AUC From Dosing to Last Measurable Concentration (AUClast) of MT-3724	Blood samples were collected at indicated timepoints for the determination of AUC (0-4), AUC (0-infinity) and AUClast.	Part 1 and 2: Days 1, 3 and 12
Primary	Part 1 and 2: Half Life (t1/2) of MT-3724	Blood samples were collected at indicated timepoints for the analysis of t1/2 of MT-3724.	Part 1 and 2: Days 1, 3 and 12
Primary	Part 1 and 2: Volume of Distribution (Vz) of MT-3724	Blood samples were collected at indicated timepoints for the analysis of Vz of MT-3724.	Part 1 and 2: Days 1, 3 and 12
Primary	Part 1 and 2: Clearance (CL) of MT-3724	Blood samples were collected at indicated timepoints for the analysis of CL of MT-3724.	Part 1 and 2: Days 1, 3 and 12
Primary	Part 1 and 2: Absolute Values of Cluster of Differentiation 19 Plus (CD19+) for B-cell Lymphocytes	CD19+ cells in the peripheral blood were counted as measures of malignant B-cells and were measured by flow cytometry. Flow cytometry is a technique for counting and examining microscopic particles with an electronic detection apparatus	Part 1 and 2: Cycle 1: Days 8 and 23; Cycle 3: Day1; Cycle 5: Day 1 and Day 120 (end of study)
Primary	Part 1 and 2: Number of Participants With Positive Anti-drug Antibody (ADA) Confirmed	Blood samples were collected to analyze the presence of ADA that bind MT-3724. Number of participants with positive ADA confirmed has been presented.	Part 1 and 2: Cycle 1, Day 23; Cycle 2, Day 1; Cycle 3, Day 1; Cycle 4, Day 1; Cycle 5, Day 1 and Day 120 (end of study)
Primary	Part 3: Number of Participants Reporting Serious Treatment-emergent Adverse Events (TEAEs) and Non-serious TEAEs	An adverse event is any untoward medical occurrence or clinical investigation in a participant administered a pharmaceutical product(s) and which does not necessarily have to have a causal relationship with this experimental treatment(s). SAE is any untoward medical occurrence, at any dose; is fatal or life-threatening, is life-threatening, results in permanently disabling; results in unplanned in-patient hospitalization or prolongation of existing hospitalization; results in a congenital abnormality or birth defect; important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when based upon appropriate medical judgment, they may jeopardize the participant or may require medical or surgical intervention.	Up to Day 45
Primary	Part 3: Number of Participants With Clinically Significant Laboratory Parameters	Blood samples were collected at indicated timepoints for the analysis of laboratory parameters.	Up to Day 45
Primary	Part 3: Number of Participants With Clinically Significant Electrocardiogram (ECG) Values	Standard resting 12-lead ECG assessments was performed after the participant has rested quietly for at least 5 minutes in supine or semi-recumbent position.	Up to Day 26
Primary	Part 3: Number Participants With Clinically Significant Vital Signs	Vital signs including systolic and diastolic blood pressure, respiratory rate, heart rate and body temperature were assessed at indicated time points.	Up to Day 45
Primary	Part 3: Number of Participants With Clinically Significant Physical Findings	Physical examination was performed by a physician or a qualified delegate at the investigating site.	Up to Day 26
Primary	Part 4: Overall Response Rate (ORR) in MT-3724 Treated Participants With Relapsed or Refractory DLBCL	Overall response rate is defined as the percentage of participants with either a CR or a PR as determined by independent, blinded central review.	Up to Day 45
Secondary	Part 1 and 2: Number of Participants Reporting Worst Case Serious Treatment Emergent Adverse Events (TEAEs) and Non-serious TEAEs	An adverse event is any untoward medical occurrence or clinical investigation in a participant administered a pharmaceutical product(s) and which does not necessarily have to have a causal relationship with this experimental treatment(s). SAE is any untoward medical occurrence, at any dose; is fatal or life-threatening, is life-threatening, results in permanently disabling; results in unplanned in-patient hospitalization or prolongation of existing hospitalization; results in a congenital abnormality or birth defect; important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when based upon appropriate medical judgment, they may jeopardize the participant or may require medical or surgical intervention.	Up to Day 45
Secondary	Part 3: ORR in MT-3724 Treated Participants With Relapsed or Refractory DLBCL by the Lugano Classification for Lymphoma	Overall response rate is defined as the percentage of participants with either a complete response (CR) or a partial response (PR) as determined by independent, blinded central review board.	Up to Day 45
Secondary	Part 3: ORR in MT-3724 Treated Participants With Relapsed or Refractory DLBCL	Overall response rate is defined as the percentage of participants with either a CR or a PR as determined by investigator assessment.	Up to Day 45
Secondary	Part 3: Duration of Tumor Response (DOR) in MT-3724 Treated Participants With Relapsed or Refractory DLBCL	DOR defined as time from initial documentation of tumor response (CR or PR) to disease progression.	Up to Day 45
Secondary	Part 3: Disease Control Rate (DCR) in MT-3724 Treated Participants With Relapsed or Refractory DLBCL	DCR defined as percentage of participants who have achieved CR, PR and stable disease.	Up to Day 45
Secondary	Part 3: Cmax of MT-3724 Monotherapy in Participants With Relapsed or Refractory DLBCL	Blood samples were planned to be collected at indicated timepoints for the analysis of Cmax of MT-3724 monotherapy.	Up to Day 45
Secondary	Part 3: Tmax of MT-3724 Monotherapy in Participants With Relapsed or Refractory DLBCL	Blood samples were planned to be collected at indicated timepoints for the analysis of tmax of MT-3724 monotherapy.	Up to Day 45
Secondary	Part 3: AUC (0-4), AUC (0-infinity) and AUClast of MT-3724 Monotherapy in Participants With Relapsed or Refractory DLBCL	Blood samples were planned to be collected at indicated timepoints for the analysis of AUC (0-4), AUC (0-infinity) and AUClast of MT-3724 monotherapy.	Up to Day 45
Secondary	Part 3: t1/2 of MT-3724 Monotherapy in Participants With Relapsed or Refractory DLBCL	Blood samples were planned to be collected at indicated timepoints for the analysis of t1/2 of MT-3724 monotherapy.	Up to Day 45
Secondary	Part 3: Vz of MT-3724 Monotherapy in Participants With Relapsed or Refractory DLBCL	Blood samples were planned to be collected at indicated timepoints for the analysis of Vz of MT-3724 monotherapy.	Up to Day 45
Secondary	Part 3: CL of MT-3724 Monotherapy in Participants With Relapsed or Refractory DLBCL	Blood samples were planned to be collected at indicated timepoints for the analysis of CL of MT-3724 monotherapy	Up to Day 45
Secondary	Part 3: PD of MT-3724 Measured by B-cell Count in Participants With Relapsed or Refractory DCBCL	Pharmacodynamics of MT-3724 was planned to be measured by B-cell count in participants with relapsed of refractory DCBCL using flow cytometry.	Up to Day 45
Secondary	Part 3: PD of MT-3724 Measured by Immunophenotyping in Participants With Relapsed or Refractory DCBCL	Pharmacodynamics of MT-3724 was planned to be measured by immunophenotyping in participants with relapsed of refractory DCBCL using flow cytometry.	Up to Day 45
Secondary	Part 3: PD of MT-3724 Measured by Circulating Immunoglobulins in Participants With Relapsed or Refractory DCBCL	Pharmacodynamics of MT-3724 was planned to be measured by circulating immunoglobulins in participants with relapsed of refractory DCBCL.	Up to Day 45
Secondary	Part 3: Number of Participants With ADA When Treated With MT-3724	Blood samples were planned to be collected to analyze the presence of ADA that bind MT-3724.	Up to Day 45
Secondary	Part 4: DOR in MT-3724 Treated Participants With Relapsed or Refractory DLBCL	Duration of response was defined as the time from the first occurrence of either complete or partial response to first documented evidence of disease recurrence or progression. Participants without evidence of progression were planned to be censored at time of last disease assessment. Only responders (CR or PR) were planned to be included for this analysis.	Up to Day 45
Secondary	Part 4: Number of Participants Reporting Serious Treatment-emergent Adverse Events (TEAEs) and Non-serious TEAEs	An adverse event is any untoward medical occurrence or clinical investigation in a participant administered a pharmaceutical product(s) and which does not necessarily have to have a causal relationship with this experimental treatment(s). SAE is any untoward medical occurrence, at any dose; is fatal or life-threatening, is life-threatening, results in permanently disabling; results in unplanned in-patient hospitalization or prolongation of existing hospitalization; results in a congenital abnormality or birth defect; important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when based upon appropriate medical judgment, they may jeopardize the participant or may require medical or surgical intervention.	Up to Day 45
Secondary	Part 4: Number of Participants With SAEs	A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement or is associated with liver injury and impaired liver function.	Up to Day 45
Secondary	Part 4: Number of Participants With Clinically Significant Laboratory Parameters	Blood samples were planned to be collected for the analysis of laboratory parameters.	Up to Day 45
Secondary	Part 4: Number Participants With Clinically Significant Vital Signs	Vital signs parameters including systolic and diastolic blood pressure, heart rate, respiration rate, body temperature and body weight were planned to be analyzed.	Up to Day 45
Secondary	Part 4: Number of Participants With Clinically Significant ECG Values	Standard resting 12-lead ECG assessments was planned to be performed after the participant has rested quietly for at least 5 minutes in supine or semi-recumbent position.	Up to Day 26
Secondary	Part 4: Number of Participants With Adverse Events Suggestive of Cardiotoxicity	Number of participants with any adverse events leading to cardiotoxicity when treated with MT-3724 was planned to be analyzed.	Up to Day 26
Secondary	Part 4: ORR in MT-3724 Treated Participants With Relapsed or Refractory DLBCL	Overall response rate was defined as the percentage of participants with either a CR or a PR as determined by investigator assessment.	Up to Day 45
Secondary	Part 4: DCR in MT-3724 Treated Participants With Relapsed or Refractory DLBCL	DCR was defined as percentage of participants who has achieved CR, PR and stable disease.	Up to Day 45
Secondary	Part 4: Progression-free Survival (PFS) in MT-3724 Treated Participants With Relapsed or Refractory DLBCL	Progression-free survival was defined as the time from study enrollment to the earliest date of disease progression or death from any cause.	Up to Day 45
Secondary	Part 4: Overall Survival (OS) in MT-3724 Treated Participants With Relapsed or Refractory DLBCL	Overall survival was defined as the time from study enrollment to death from any cause.	Up to Day 45
Secondary	Part 4: Cmax of MT-3724 Monotherapy in Participants With Relapsed or Refractory DLBCL	Blood samples were planned to be collected at indicated timepoints for the analysis of Cmax of MT-3724 monotherapy.	Up to Day 45
Secondary	Part 4: Tmax of MT-3724 Monotherapy in Participants With Relapsed or Refractory DLBCL	Blood samples were planned to be collected at indicated timepoints for the analysis of Tmax of MT-3724 monotherapy.	Up to Day 45
Secondary	Part 4: AUC (0-4), AUC (0-infinity) and AUClast of MT-3724 Monotherapy in Participants With Relapsed or Refractory DLBCL	Blood samples were planned to be collected at indicated timepoints for the analysis of AUC (0-4), AUC (0-infinity) and AUClast of MT-3724 monotherapy.	Up to Day 45
Secondary	Part 4: t1/2 of MT-3724 Monotherapy in Participants With Relapsed or Refractory DLBCL	Blood samples were planned to be collected at indicated timepoints for the analysis of t1/2 of MT-3724 monotherapy.	Up to Day 45
Secondary	Part 4: Vz of MT-3724 Monotherapy in Participants With Relapsed or Refractory DLBCL	Blood samples were planned to be collected at indicated timepoints for the analysis of Vz of MT-3724 monotherapy.	Up to Day 45
Secondary	Part 4: CL of MT-3724 Monotherapy in Participants With Relapsed or Refractory DLBCL	Blood samples were planned to be collected at indicated timepoints for the analysis of CL of MT-3724 monotherapy.	Up to Day 45
Secondary	Part 4: PD of MT-3724 Measured by B-cell Count in Participants With Relapsed or Refractory DCBCL	Pharmacodynamics of MT-3724 was planned to be measured by B-cell count in participants with relapsed of refractory DCBCL using flow cytometry.	Up to Day 45
Secondary	Part 4: PD of MT-3724 Measured by Immunophenotyping in Participants With Relapsed or Refractory DCBCL	Pharmacodynamics of MT-3724 was planned to be measured by immunophenotyping in participants with relapsed of refractory DCBCL using flow cytometry.	Up to Day 45
Secondary	Part 4: PD of MT-3724 Measured by Circulating Immunoglobulins in Participants With Relapsed or Refractory DCBCL	Pharmacodynamics of MT-3724 was planned to be measured by circulating immunoglobulins in participants with relapsed of refractory DCBCL.	Up to Day 45
Secondary	Part 4: Number of Participants With ADA When Treated With MT-3724	Blood samples were planned to be collected to analyze the presence of ADA that bind MT-3724.	Up to Day 45